Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice

Li,Peicheng; Tang,Zhaosheng; Wang,Lin; Feng,Bo

doi:10.3892/mmr.2017.6978

Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice

Authors:
- Peicheng Li
- Zhaosheng Tang
- Lin Wang
- Bo Feng
View Affiliations

Affiliations: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200000, P.R. China
Published online on: July 14, 2017 https://doi.org/10.3892/mmr.2017.6978
Pages: 3421-3426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucagon-like peptide-1 (GLP-1) can protect arteriosclerotic lesions in apolipoprotein-E deficient (ApoE-/-) mice. Advanced glycation end products (AGEs)/receptor for advanced glycation end products (RAGE) interaction serves a key role in the development of diabetic vascular complications. The present study examined whether the GLP-1 analogue liraglutide can ameliorate atherogenesis via inhibiting AGEs-induced RAGE expression. Male ApoE-/- mice (age, 10 weeks) were divided into control, GLP-1, AGEs and AGEs+GLP-1 group. All mice were fed a high-fat diet. The AGEs and AGEs+GLP-1 groups were treated with intraperitoneal injection of AGEs (30 mg/kg/day). The GLP-1 and AGEs+GLP-1 groups were treated with subcutaneous injections of liraglutide (0.4 mg/kg/day). After 9 weeks, blood was drawn and the aortas were rapidly procured. The serum levels of AGEs, soluble RAGE (sRAGE), stromal cell-derived factor-1α (SDF-1α), total cholesterol and triacylglycerol were measured. Atherosclerotic plaque area was determined by Sudan IV staining. The mRNA and protein expression levels of RAGE were determined using reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. The results demonstrated that AGEs treatment increased serum AGEs levels, increased the expression of RAGE in the aorta, and aggravated atherosclerotic lesions compared with the control. Liraglutide treatment reduced serum AGEs levels, reduced the expression of RAGE in aorta, and relieved atherosclerotic lesions compared with the control. In conclusion, these data suggested that liraglutide serves an anti-atherosclerotic effect via inhibiting AGEs-induced RAGE expression in ApoE-/- mice. These findings provide novel evidence for the use of GLP-1-type agents for the treatment of diabetic vascular complications.

View Figures

View References

1	Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321. 2011. View Article : Google Scholar : PubMed/NCBI
2	Haffner SM, Lehto S, Rönnemaa T, Pyörälä K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:229–234. 1998. View Article : Google Scholar : PubMed/NCBI
3	Fowler MJ: Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes. 26:77–82. 2008. View Article : Google Scholar
4	Scheen AJ and Paquot N: Blood glucose control and prevention of microangiopathy and macroangiopathy in type 2 diabetes. Rev Med Liege. 58:265–270. 2003.PubMed/NCBI
5	Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, et al: Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol. 171:723–734. 2014. View Article : Google Scholar : PubMed/NCBI
6	Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J and Victorino GP: Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides. 30:1735–1741. 2009. View Article : Google Scholar : PubMed/NCBI
7	le Kim Chung T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T and Nakaya Y: Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 390:613–618. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 46:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
9	Huttunen HJ, Fages C and Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 274:19919–19924. 1999. View Article : Google Scholar : PubMed/NCBI
10	Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 50:2792–2808. 2001. View Article : Google Scholar : PubMed/NCBI
11	Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation. 108:1070–1077. 2003. View Article : Google Scholar : PubMed/NCBI
12	Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D and Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 4:1025–1031. 1998. View Article : Google Scholar : PubMed/NCBI
13	Feng B, Xu L, Wang H, Yan X, Xue J, Liu F and Hu JF: Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta. 1812:1130–1137. 2011. View Article : Google Scholar : PubMed/NCBI
14	Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM and Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 91:11704–11708. 1994. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, Kitamine T, Shimada M, Ohashi K, Harada K, et al: Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res. 40:1677–1685. 1999.PubMed/NCBI
17	Chrysant SG and Chrysant GS: Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 109:1681–1685. 2012. View Article : Google Scholar : PubMed/NCBI
18	Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R and Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 59:1030–1037. 2010. View Article : Google Scholar : PubMed/NCBI
19	Knudsen LB: Liraglutide: The therapeutic promise from animal models. Int J Clin Pract Suppl. 4–11. 2010. View Article : Google Scholar : PubMed/NCBI
20	Vlassara H and Palace MR: Diabetes and advanced glycation endproducts. J Intern Med. 251:87–101. 2002. View Article : Google Scholar : PubMed/NCBI
21	Fukami K, Yamagishi S and Okuda S: Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 20:2395–2402. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yamagishi S, Fukami K and Matsui T: Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol. 14:22015. View Article : Google Scholar : PubMed/NCBI
23	Sourris KC and Forbes JM: Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets. 10:42–50. 2009. View Article : Google Scholar : PubMed/NCBI
24	Daffu G, del Pozo CH, O'Shea KM, Ananthakrishnan R, Ramasamy R and Schmidt AM: Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci. 14:19891–19910. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kim W and Egan JM: The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 60:470–512. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ishibashi Y, Matsui T, Takeuchi M and Yamagishi S: Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 391:1405–1408. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chen S, Yin L, Xu Z, An FM, Liu AR, Wang Y, Yao WB and Gao XD: Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis. Neurosci Lett. 612:193–198. 2016. View Article : Google Scholar : PubMed/NCBI
28	Hudson BI, Harja E, Moser B and Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein? Arterioscler Thromb Vasc Biol. 25:879–882. 2005. View Article : Google Scholar : PubMed/NCBI
29	Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E and Gastaldelli A: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 91:4628–4634. 2006. View Article : Google Scholar : PubMed/NCBI
30	Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M and Geroldi D: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 25:1032–1037. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W and Ratajczak J: The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 20:1915–1924. 2006. View Article : Google Scholar : PubMed/NCBI
32	Kucia M, Reca R, Jala VR, Dawn B, Ratajczak J and Ratajczak MZ: Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. Leukemia. 19:1118–1127. 2005. View Article : Google Scholar : PubMed/NCBI
33	Liu Z, Stanojevic V, Avadhani S, Yano T and Habener JF: Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. Diabetologia. 54:2067–2076. 2011. View Article : Google Scholar : PubMed/NCBI